CONCLUSIONS
Overall, our study findings suggest that patients with a history of
cancer who are hospitalized with SARS-CoV-2 are not at greater risk for
AKI, though they are at higher risk for mortality as compared to
hospitalized patients without a cancer diagnosis. The increased risk in
mortality appears driven by patients with pulmonary neoplasms. Patients
with genitourinary malignancies do not appear to be at higher risk for
mortality or for AKI compared to those without malignancy.
This finding is of great clinical importance as we navigate the
“new-normal” phase of the COVID19 pandemic. Healthcare providers must
guide patients through weighing the risks of delaying therapy against
the risks of contracting COVID19 in the nosocomial setting.
Understanding that the risk of adverse outcomes in patients with
histories of genitourinary malignancy is similar to that of the general
public may help guide patients through this challenging and anxiety
provoking risk-benefit analysis. Further study with a larger cohort of
genitourinary malignancy patients in a prospective manner is warranted.